ArticleBMC microbiology2026
Genetic characterization of tigecycline and carbapenem resistant Acinetobacter baumannii in a tertiary care hospital of Northern India.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcinetobacter baumannii has emerged as a predominant cause of hospital-acquired infections worldwide, posing a significant challenge due to its extraordinary ability to acquire resistance to multiple antibiotics. According to recent data, infections caused by multidrug-resistant A. baumannii lead to increased morbidity, longer hospital stays, and higher healthcare costs. Carbapenems and tigecycline have historically provided reliable treatment for A. baumannii infections; however, recent global trends indicate a significant increase in carbapenem and tigecycline resistance among circulating isolates.
objectivesThe study aimed to determine the prevalence and genetic characterization of tigecycline resistance in A. baumannii (TRAB) among carbapenem-resistant isolates and to assess the transferability of carbapenem and tetracycline resistance genes between isolates.
methodsAll 160 clinical isolates were obtained from admitted patients in SGPGIMS, Lucknow (India). Identification of the isolates was performed using MALDI-TOF MS, followed by antimicrobial susceptibility testing (AST), determination of minimum inhibitory concentrations (MICs), and PCR-based detection of carbapenem and tetracycline resistance genes. The transferability of resistance genes was further assessed through conjugation assays, and the AST of transconjugant isolates was evaluated accordingly.
resultsA total of 32 out of 160 isolates (20%) were resistant to both carbapenem and tigecycline. All these isolates were multidrug-resistant (MDR), exhibiting resistance to more than three classes of antibiotics. Genetic screening showed the blaNDM and blaOXA-48 carbapenemase genes in 25% and 18.75% of the respective isolates; blaKPC was not detected. Among tetracycline resistance genes, only tet(B) was present in 15.63% (5/32) of the isolates; other genes such as tet(A), tet(K), tet(M), and tet(S) were absent. Both carbapenemase and tetracycline resistance genes were plasmid-mediated, and often co-existed in the same isolates. However, only the carbapenemase genes were transferable by conjugation; the tetracycline resistance genes were not transferable.
conclusionsThe increasing prevalence of carbapenem and tigecycline-resistant A. baumannii is primarily linked to plasmid-mediated carbapenemase genes, which facilitate their spread. In contrast, tigecycline resistance, although present, appears to be non-transferable under the conditions studied.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.